• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Inspire medical systems upsizes IPO

biospectrumasiaMay 07, 2018

Tag: obstructive sleep apnea , Inspire Medical Systems , IPO

Inspire Medical Systems, which sells an implanted device for treating obstructive sleep apnea, raised $108 million by offering 6.75 million shares at $16, the high end of the range of $14 to $16. It had previously filed to offer 5.0 million shares at the same range. Inspire Medical Systems plans to list on the NYSE under the symbol INSP. BofA Merrill Lynch and Goldman Sachs acted as lead managers on the deal.

The debut date has not been announced yet.

Register as Visitor to CPhI China 2018!

Previous:New study gives hope to fight minimal tumors

Next:Daily aspirin linked to higher risk in men

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Inspire medical systems upsizes IPO | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

BAF-312(SiponiMod)

BAF-312(SiponiMod)
cationic liposome DLin-MC3-DMA丨1224606-06-7

cationic liposome DLin-MC3-DMA丨1224606-06-7
Lipopeptide

Lipopeptide

DIPOTASSIUM GLYCYRRHIZINATE

DIPOTASSIUM GLYCYRRHIZINATE
Sodium Tripolyphosphate(STPP)

Sodium Tripolyphosphate(STPP)
Sodium Tripolyphosphate

Sodium Tripolyphosphate
Alpha Lipoic Acid

Alpha Lipoic Acid
Alpha Lipoic acid / R- Alpha Lipoic acid

Alpha Lipoic acid / R- Alpha Lipoic acid
K2G (Dipotassium Glycyrrhizinate) from GMP factory in China

K2G (Dipotassium Glycyrrhizinate) from GMP factory in China
Tripotassium Phosphate Heptahydrate

Tripotassium Phosphate Heptahydrate

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service